Sangamo BioSciences reported $2.8M in Interest Income for its fiscal quarter ending in June of 2023.





Interest Income Change Date
Alnylam Pharmaceuticals USD 26.63M 2.05M Dec/2025
Bayer EUR 169M 39M Dec/2025
BioCryst Pharmaceuticals USD -0.13 3.59M Dec/2024
Biogen USD 37.9M 700K Mar/2026
BioMarin Pharmaceutical USD 22.56M 3.35M Mar/2026
Compugen USD 954K 116K Sep/2025
CSL USD 18M 1000K Dec/2024
Gilead Sciences USD 95M 7M Dec/2025
GlaxoSmithKline GBP 22M 96M Mar/2026
Ionis Pharmaceuticals USD -0.66 0.29 Dec/2024
J&J USD 2.14 237M Mar/2026
Karyopharm Therapeutics USD -0.15 0.11 Dec/2024
Merck USD 69M 27M Dec/2025
Pfizer USD 115M 51M Mar/2026
Sanofi EUR 33M 81M Dec/2025
Sarepta Therapeutics USD 8.74M 359K Dec/2025
Tectonic Therapeutic USD 1.74M 217K Dec/2024
Ultragenyx Pharmaceutical USD 6.51M 649K Dec/2025
Vertex Pharmaceuticals USD 114.8M 7.1M Mar/2026